# UNITED THERAPEUTICS Corp: financial statements, quarterly

UTHR · Nasdaq · CIK 1082554 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/uthr.md) · [Financials](/companies/uthr/financials.md) · [Filings](/companies/uthr/filings.md) · [Insiders](/companies/uthr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/uthr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [609](/filings/0001082554-24-000047.md) | [615 d](/filings/0001082554-26-000006.md) | [678](/filings/0001082554-25-000023.md) | [715](/filings/0001628280-25-036541.md) | [749](/filings/0001082554-25-000034.md) | [736 d](/filings/0001082554-26-000006.md) | [794](/filings/0001082554-26-000020.md) | [799](/filings/0001082554-26-000027.md) | [800](/filings/0001082554-25-000034.md) | [790 d](/filings/0001082554-26-000006.md) | [782](/filings/0001082554-26-000020.md) | [783](/filings/0001082554-26-000027.md) |
| Cost of revenue | $m | [70.1](/filings/0001082554-24-000047.md) | [71.0 d](/filings/0001082554-26-000006.md) | [72.9](/filings/0001082554-25-000023.md) | [77.8](/filings/0001628280-25-036541.md) | [83.1](/filings/0001082554-25-000034.md) | [75.9 d](/filings/0001082554-26-000006.md) | [92.5](/filings/0001082554-26-000020.md) | [87.6](/filings/0001082554-26-000027.md) | [101](/filings/0001082554-25-000034.md) | [103 d](/filings/0001082554-26-000006.md) | [133](/filings/0001082554-26-000020.md) | [99.5](/filings/0001082554-26-000027.md) |
| Gross profit | $m | [539](/filings/0001082554-24-000047.md) | [544 d](/filings/0001082554-26-000006.md) | [605](/filings/0001082554-25-000023.md) | [637](/filings/0001628280-25-036541.md) | [666](/filings/0001082554-25-000034.md) | [660 d](/filings/0001082554-26-000006.md) | [702](/filings/0001082554-26-000020.md) | [711](/filings/0001082554-26-000027.md) | [699](/filings/0001082554-25-000034.md) | [687 d](/filings/0001082554-26-000006.md) | [648](/filings/0001082554-26-000020.md) | [684](/filings/0001082554-26-000027.md) |
| Research and development | $m | [84.7](/filings/0001082554-24-000047.md) | [151 d](/filings/0001082554-26-000006.md) | [104](/filings/0001082554-25-000023.md) | [140](/filings/0001628280-25-036541.md) | [104](/filings/0001082554-25-000034.md) | [134 d](/filings/0001082554-26-000006.md) | [149](/filings/0001082554-26-000020.md) | [134](/filings/0001082554-26-000027.md) | [128](/filings/0001082554-25-000034.md) | [140 d](/filings/0001082554-26-000006.md) | [138](/filings/0001082554-26-000020.md) | [146](/filings/0001082554-26-000027.md) |
| Selling, general and administrative | $m | [128](/filings/0001082554-24-000047.md) | [132 d](/filings/0001082554-26-000006.md) | [144](/filings/0001082554-25-000023.md) | [178](/filings/0001628280-25-036541.md) | [219](/filings/0001082554-25-000034.md) | [169 d](/filings/0001082554-26-000006.md) | [170](/filings/0001082554-26-000020.md) | [213](/filings/0001082554-26-000027.md) | [183](/filings/0001082554-25-000034.md) | [191 d](/filings/0001082554-26-000006.md) | [184](/filings/0001082554-26-000020.md) | [207](/filings/0001082554-26-000027.md) |
| Operating income | $m | [327](/filings/0001082554-24-000047.md) | [260 d](/filings/0001082554-26-000006.md) | [356](/filings/0001082554-25-000023.md) | [320](/filings/0001628280-25-036541.md) | [343](/filings/0001082554-25-000034.md) | [358 d](/filings/0001082554-26-000006.md) | [383](/filings/0001082554-26-000020.md) | [365](/filings/0001082554-26-000027.md) | [389](/filings/0001082554-25-000034.md) | [357 d](/filings/0001082554-26-000006.md) | [326](/filings/0001082554-26-000020.md) | [331](/filings/0001082554-26-000027.md) |
| Interest expense | $m | [15.6](/filings/0001082554-23-000031.md) | [15.1 d](/filings/0001082554-24-000005.md) | [13.3](/filings/0001082554-24-000025.md) | [11.6](/filings/0001628280-25-036541.md) | [10.1](/filings/0001082554-25-000034.md) | [7.9 d](/filings/0001082554-26-000006.md) | [6.1](/filings/0001082554-26-000020.md) | [7.3](/filings/0001082554-26-000027.md) | [3.0](/filings/0001082554-25-000034.md) | [3.1 d](/filings/0001082554-26-000006.md) | [3.0](/filings/0001082554-26-000020.md) | [2.9](/filings/0001082554-26-000027.md) |
| Income tax | $m | [84.2](/filings/0001082554-24-000047.md) | [78.3 d](/filings/0001082554-26-000006.md) | [92.0](/filings/0001082554-25-000023.md) | [77.2](/filings/0001628280-25-036541.md) | [79.5](/filings/0001082554-25-000034.md) | [95.2 d](/filings/0001082554-26-000006.md) | [101](/filings/0001082554-26-000020.md) | [98.9](/filings/0001082554-26-000027.md) | [99.3](/filings/0001082554-25-000034.md) | [79.7 d](/filings/0001082554-26-000006.md) | [43.4](/filings/0001082554-26-000020.md) | [39.7](/filings/0001082554-26-000027.md) |
| Net income | $m | [268](/filings/0001082554-24-000047.md) | [217 d](/filings/0001082554-26-000006.md) | [307](/filings/0001082554-25-000023.md) | [278](/filings/0001628280-25-036541.md) | [309](/filings/0001082554-25-000034.md) | [301 d](/filings/0001082554-26-000006.md) | [322](/filings/0001082554-26-000020.md) | [310](/filings/0001082554-26-000027.md) | [339](/filings/0001082554-25-000034.md) | [364 d](/filings/0001082554-26-000006.md) | [275](/filings/0001082554-26-000020.md) | [333](/filings/0001082554-26-000027.md) |
| Diluted EPS | $ per share | [5.38](/filings/0001082554-24-000047.md) | not reported | [6.17](/filings/0001082554-25-000023.md) | [5.85](/filings/0001628280-25-036541.md) | [6.39](/filings/0001082554-25-000034.md) | not reported | [6.63](/filings/0001082554-26-000020.md) | [6.41](/filings/0001082554-26-000027.md) | [7.16](/filings/0001082554-25-000034.md) | not reported | [5.82](/filings/0001082554-26-000020.md) | [7.27](/filings/0001082554-26-000027.md) |
| Basic EPS | $ per share | [5.71](/filings/0001082554-24-000047.md) | not reported | [6.52](/filings/0001082554-25-000023.md) | [6.26](/filings/0001628280-25-036541.md) | [6.93](/filings/0001082554-25-000034.md) | not reported | [7.18](/filings/0001082554-26-000020.md) | [6.86](/filings/0001082554-26-000027.md) | [7.73](/filings/0001082554-25-000034.md) | not reported | [6.32](/filings/0001082554-26-000020.md) | [7.82](/filings/0001082554-26-000027.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1,108](/filings/0001082554-23-000031.md) | [1,208](/filings/0001082554-25-000005.md) | [1,252](/filings/0001082554-24-000025.md) | [1,356](/filings/0001082554-24-000035.md) | [1,554](/filings/0001082554-24-000047.md) | [1,697](/filings/0001082554-26-000006.md) | [1,900](/filings/0001082554-25-000023.md) | [1,593](/filings/0001628280-25-036541.md) | [1,340](/filings/0001082554-25-000034.md) | [1,557](/filings/0001082554-26-000027.md) | [1,280](/filings/0001082554-26-000020.md) | [1,803](/filings/0001082554-26-000027.md) |
| Current assets | $m | [3,459](/filings/0001082554-23-000031.md) | [3,551](/filings/0001082554-25-000005.md) | [3,249](/filings/0001082554-24-000025.md) | [3,620](/filings/0001082554-24-000035.md) | [4,000](/filings/0001082554-24-000047.md) | [3,874](/filings/0001082554-26-000006.md) | [3,940](/filings/0001082554-25-000023.md) | [3,827](/filings/0001628280-25-036541.md) | [3,494](/filings/0001082554-25-000034.md) | [3,703](/filings/0001082554-26-000027.md) | [2,872](/filings/0001082554-26-000020.md) | [3,484](/filings/0001082554-26-000027.md) |
| Total assets | $m | [7,024](/filings/0001082554-23-000031.md) | [7,167](/filings/0001082554-25-000005.md) | [6,495](/filings/0001082554-24-000025.md) | [6,723](/filings/0001082554-24-000035.md) | [7,123](/filings/0001082554-24-000047.md) | [7,364](/filings/0001082554-26-000006.md) | [7,744](/filings/0001082554-25-000023.md) | [7,908](/filings/0001628280-25-036541.md) | [7,351](/filings/0001082554-25-000034.md) | [7,880](/filings/0001082554-26-000027.md) | [6,714](/filings/0001082554-26-000020.md) | [7,220](/filings/0001082554-26-000027.md) |
| Current liabilities | $m | [744](/filings/0001082554-23-000031.md) | [804](/filings/0001082554-25-000005.md) | [861](/filings/0001082554-24-000025.md) | [832](/filings/0001082554-24-000035.md) | [873](/filings/0001082554-24-000047.md) | [738](/filings/0001082554-26-000006.md) | [722](/filings/0001082554-25-000023.md) | [527](/filings/0001628280-25-036541.md) | [546](/filings/0001082554-25-000034.md) | [561](/filings/0001082554-26-000027.md) | [599](/filings/0001082554-26-000020.md) | [608](/filings/0001082554-26-000027.md) |
| Total liabilities | $m | [1,312](/filings/0001082554-23-000031.md) | [1,182](/filings/0001082554-25-000005.md) | [1,157](/filings/0001082554-24-000025.md) | [1,026](/filings/0001082554-24-000035.md) | [1,022](/filings/0001082554-24-000047.md) | [920](/filings/0001082554-26-000006.md) | [937](/filings/0001082554-25-000023.md) | [734](/filings/0001628280-25-036541.md) | [761](/filings/0001082554-25-000034.md) | [784](/filings/0001082554-26-000027.md) | [813](/filings/0001082554-26-000020.md) | [820](/filings/0001082554-26-000027.md) |
| Shareholders' equity | $m | [5,712](/filings/0001082554-24-000047.md) | [5,985](/filings/0001082554-26-000006.md) | [5,338](/filings/0001628280-25-036541.md) | [5,697](/filings/0001082554-25-000034.md) | [6,101](/filings/0001082554-25-000034.md) | [6,444](/filings/0001082554-26-000027.md) | [6,807](/filings/0001082554-26-000027.md) | [7,174](/filings/0001082554-26-000027.md) | [6,590](/filings/0001082554-25-000034.md) | [7,096](/filings/0001082554-26-000027.md) | [5,901](/filings/0001082554-26-000027.md) | [6,400](/filings/0001082554-26-000027.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [346 d](/filings/0001082554-24-000047.md) | [151 d](/filings/0001082554-26-000006.md) | [377](/filings/0001082554-25-000023.md) | [232 d](/filings/0001628280-25-036541.md) | [377 d](/filings/0001082554-25-000034.md) | [341 d](/filings/0001082554-26-000006.md) | [461](/filings/0001082554-26-000020.md) | [192 d](/filings/0001082554-26-000027.md) | [562 d](/filings/0001082554-25-000034.md) | [346 d](/filings/0001082554-26-000006.md) | [463](/filings/0001082554-26-000020.md) | [314 d](/filings/0001082554-26-000027.md) |
| Capital expenditure | $m | [65.7 d](/filings/0001082554-24-000047.md) | [78.7 d](/filings/0001082554-26-000006.md) | [38.2](/filings/0001082554-25-000023.md) | [45.1 d](/filings/0001628280-25-036541.md) | [76.5 d](/filings/0001082554-25-000034.md) | [86.7 d](/filings/0001082554-26-000006.md) | [74.9](/filings/0001082554-26-000020.md) | [62.2 d](/filings/0001082554-26-000027.md) | [211 d](/filings/0001082554-25-000034.md) | [173 d](/filings/0001082554-26-000006.md) | [101](/filings/0001082554-26-000020.md) | [108 d](/filings/0001082554-26-000027.md) |
| Share repurchases | $m | [0.0 d](/filings/0001082554-24-000047.md) | [0.0 d](/filings/0001082554-26-000006.md) | [1,000](/filings/0001082554-25-000023.md) | [0.0 d](/filings/0001628280-25-036541.md) | [0.0 d](/filings/0001082554-25-000034.md) | [0.0 d](/filings/0001082554-26-000006.md) | [0.0](/filings/0001082554-26-000020.md) | [0.0 d](/filings/0001082554-26-000027.md) | [1,000 d](/filings/0001082554-25-000034.md) | [0.0 d](/filings/0001082554-26-000006.md) | [1,500](/filings/0001082554-26-000020.md) | [0.0 d](/filings/0001082554-26-000027.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [48.7](/filings/0001082554-23-000031.md) | [49.6](/filings/0001082554-24-000025.md) | [49.5](/filings/0001082554-24-000035.md) | [49.7](/filings/0001082554-24-000047.md) | [49.7](/filings/0001082554-25-000023.md) | [47.5](/filings/0001628280-25-036541.md) | [48.4](/filings/0001082554-25-000034.md) | [48.6](/filings/0001082554-26-000020.md) | [48.3](/filings/0001082554-26-000027.md) | [47.3](/filings/0001082554-25-000034.md) | [47.2](/filings/0001082554-26-000020.md) | [45.8](/filings/0001082554-26-000027.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 42,890,692 at 2026-07-29, from the cover of the [10-Q filed 2026-08-05](/filings/0001082554-26-000027.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.